| 51 |
31101118 | Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase. | 2019 May 17 |
1 |
| 52 |
31296812 | [Hereditary Breast and Ovarian Cancer Syndrome]. | 2019 Jul |
1 |
| 53 |
28146604 | The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury. | 2018 Jan |
1 |
| 54 |
29382645 | First PARP Inhibitor Ok'd for Breast Cancer. | 2018 Mar |
1 |
| 55 |
29465803 | Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells. | 2018 Apr |
1 |
| 56 |
29582690 | Olaparib for the treatment of breast cancer. | 2018 Jun |
1 |
| 57 |
29748182 | A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. | 2018 Sep 1 |
1 |
| 58 |
29898896 | Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease. | 2018 Sep |
1 |
| 59 |
29983873 | Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells. | 2018 Jun 19 |
2 |
| 60 |
30057890 | Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status. | 2018 |
1 |
| 61 |
30084837 | Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. | 2018 Oct 15 |
1 |
| 62 |
30232143 | Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response. | 2018 Dec |
1 |
| 63 |
30333000 | Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. | 2018 Oct 17 |
1 |
| 64 |
30353044 | Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. | 2018 Nov |
1 |
| 65 |
30555227 | Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. | 2018 |
1 |
| 66 |
28138868 | Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer. | 2017 Mar |
1 |
| 67 |
28323658 | Changing face of metastatic prostate cancer: the law of diminishing returns holds true. | 2017 May |
1 |
| 68 |
28395540 | Olaparib for the treatment of breast cancer. | 2017 Jun |
1 |
| 69 |
28450425 | Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. | 2017 Sep |
1 |
| 70 |
28450426 | Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. | 2017 Sep |
1 |
| 71 |
28454085 | Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. | 2017 Jul 18 |
2 |
| 72 |
28512243 | Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response. | 2017 Jun 15 |
1 |
| 73 |
28916476 | Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis. | 2017 Dec |
1 |
| 74 |
29290761 | The OlympiAD trial: who won the gold? | 2017 |
1 |
| 75 |
26899229 | Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. | 2016 |
1 |
| 76 |
26909613 | Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. | 2016 Mar 15 |
2 |
| 77 |
26934368 | Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells. | 2016 Mar |
1 |
| 78 |
26961146 | Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. | 2016 Jun |
1 |
| 79 |
26961668 | Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer. | 2016 |
1 |
| 80 |
27065456 | Homologous recombination deficiency and ovarian cancer. | 2016 Jun |
1 |
| 81 |
27345073 | The integration of BRCA testing into oncology clinics. | 2016 Jun 23 |
1 |
| 82 |
27617661 | Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. | 2016 Nov |
1 |
| 83 |
27708239 | FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. | 2016 Nov 15 |
1 |
| 84 |
27924011 | Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction. | 2016 Dec 15 |
1 |
| 85 |
25404465 | PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice. | 2015 Feb |
1 |
| 86 |
25583815 | Olaparib effective in four advanced cancers. | 2015 Jan |
1 |
| 87 |
25634209 | Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage. | 2015 Apr 1 |
1 |
| 88 |
25758301 | [Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review]. | 2015 Mar |
1 |
| 89 |
25975349 | The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. | 2015 Jul |
6 |
| 90 |
25981132 | Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. | 2015 Sep |
2 |
| 91 |
26095524 | XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. | 2015 Jun 22 |
1 |
| 92 |
26097887 | A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells. | 2015 |
2 |
| 93 |
26303225 | PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. | 2015 Oct |
1 |
| 94 |
26310895 | Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics. | 2015 Sep 18 |
1 |
| 95 |
26312527 | Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation. | 2015 |
1 |
| 96 |
26510020 | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. | 2015 Oct 29 |
2 |
| 97 |
24534203 | Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. | 2014 Jun 28 |
1 |
| 98 |
24632590 | Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. | 2014 May 30 |
1 |
| 99 |
24748377 | Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. | 2014 |
1 |
| 100 |
24784564 | Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. | 2014 May 15 |
1 |